EGFR and breast carcinoma: For instance, IMP-1710 could be useful to study the role of UCHL1 in other cancer contexts where UCHL1 is known to regulate EGFR expression, such as in EGFR+ colorectal cancers [109], drug-resistant breast cancer [43] and thyroid and glioma carcinomas [110].